Meixiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meixiang Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hui Huang
Materdicine Lab, School of Life Sciences Shanghai University Shanghai China
1 shared publication - Jianqiao Zhou
Department of Ultrasound, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
1 shared publication Shanshan Zhang
Department of Ultrasound Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P. R. China
1 shared publication- Wei Feng
Materdicine Lab School of Life Sciences Shanghai University Shanghai China
1 shared publication Xinran Song
Materdicine Laboratory, School of Life Sciences, Shanghai University, Shanghai 200444, P. R. China
1 shared publication- Yu Chen
Materdicine Lab School of Life Sciences Shanghai University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 14 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (7) , eadt8451
Single-atom–doped piezocatalyst induces copper-free cuproptosis in tumor therapy
Cuproptosis, a distinct cell death pathway, has been integrated into nanomedicine for disease theranostics. However, current nanosystems inducing cuproptosis rely on exogenous toxic copper ions, limiting the scope of biomaterials. Developing nanoplatforms that induce cuproptosis without exogenous copper holds substantial promise. Here, we engineered a two-dimensional iron (Fe) single-atom–doped molybdenum disulfide (MoS 2 ) piezocatalyst (Fe-MoS 2 ) for tumor therapy. Incorporating single Fe atoms enhances MoS 2 piezoelectric polarization via charge redistribution and modulates Fe and Mo oxidation states, enabling multifaceted enzymatic activities, including peroxidase-, glutathione oxidase–, oxidase-, and catalase-like activities. Upon ultrasound stimulation, the Fe-MoS 2 nanocatalyst generates reactive oxygen species and depletes glutathione via synergistic piezocatalytic and enzyocatalytic effects, disrupting copper ion homeostasis and inducing cuproptosis, concurrently triggering ferroptosis and ferritinophagy, which collectively enhances tumor suppression. This study represents the first paradigm to introduce a copper-free piezocatalyst for initiating cuproptosis, substantially advancing the applications of cuproptosis in tumor therapy.
- 14 February 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (7) , eadt8451
Open AccessSingle-atom–doped piezocatalyst induces copper-free cuproptosis in tumor therapy
Cuproptosis, a distinct cell death pathway, has been integrated into nanomedicine for disease theranostics. However, current nanosystems inducing cuproptosis rely on exogenous toxic copper ions, limiting the scope of biomaterials. Developing nanoplatforms that induce cuproptosis without exogenous copper holds substantial promise. Here, we engineered a two-dimensional iron (Fe) single-atom–doped molybdenum disulfide (MoS 2 ) piezocatalyst (Fe-MoS 2 ) for tumor therapy. Incorporating single Fe atoms enhances MoS 2 piezoelectric polarization via charge redistribution and modulates Fe and Mo oxidation states, enabling multifaceted enzymatic activities, including peroxidase-, glutathione oxidase–, oxidase-, and catalase-like activities. Upon ultrasound stimulation, the Fe-MoS 2 nanocatalyst generates reactive oxygen species and depletes glutathione via synergistic piezocatalytic and enzyocatalytic effects, disrupting copper ion homeostasis and inducing cuproptosis, concurrently triggering ferroptosis and ferritinophagy, which collectively enhances tumor suppression. This study represents the first paradigm to introduce a copper-free piezocatalyst for initiating cuproptosis, substantially advancing the applications of cuproptosis in tumor therapy.